Elevated 11-oxygenated androgens are not a major contributor to HPG-axis disturbances in adults with congenital adrenal hyperplasia due to 21-hydroxylase deficiency

Matthias K. Auer¹, Luisa Paizoni¹, Meike Neuner¹, Christian Lottspeich¹, Heinrich Schmidt², Martin Bidlingmaier¹, James Hawley³, Brian Keevil³, Nicole Reisch¹

¹Medizinische Klinik and Poliklinik IV, Klinikum der Universität München, LMU München, Munich, Germany

²Department of Pediatric Endocrinology, Dr. von Haunersches Children's Hospital, Klinikum der Universität München, LMU München, Munich, Germany

³Department of Clinical Biochemistry, Manchester University Foundation NHS Trust, Manchester Academic Health Sciences Centre, Southmoor Rd, Manchester, UK

11

Corresponding author:

Nicole Reisch

Medizinische Klinik and Poliklinik IV, Klinikum der Universität München

Ziemssenstr. 1

80336 München

Germany

Email: Nicole.reisch@med.uni-muenchen.de

19

Declaration of interest

21

All authors have declared that no conflict of interest exists

23

24

25

26

27

28

Highlights

- The 11-oxygenated androgens 11-ketotestosterone and 11 β -hydroxyandrostenedione are significantly elevated in men with CAH with hypogonadotropic hypogonadism and women with amenorrhea.
- Elevated 17-OHP levels in male patients and elevated testosterone levels in female patients are however the dominant predictor of HPG-axis disturbances.
- 11-oxygenated androgens are not predictive for testicular adrenal rest tumors in men with CAH
- 11-ketotestosterone and 11 β -hydroxyandrostenedione levels do not seem to be influenced by intake of oral contraceptives.

54 **Abstract**

55 **Context**

56 Hypothalamus-pituitary-gonadal (HPG)-axis disturbances are a common phenomenon in patients with
57 classic congenital adrenal hyperplasia (CAH). 11-oxygenated androgens have been suggested to play
58 a role in this context.

59 **Design**

60 Cross-sectional single center study including 89 patients (N=42 men, N=55 women) with classic CAH.

61 **Main Outcome Measures**

62 Independent predictors for hypogonadism in men and secondary amenorrhea in women with CAH with
63 a special focus on 11-ketotestosterone (11KT) and 11 β -hydroxyandrostenedione (11OHA4).

64 **Results**

65 Hypogonadotropic hypogonadism was present in 23% of men and 61% of those women currently not
66 on contraceptives suffered from irregular menstrual cycles or amenorrhea. Testicular adrenal rest
67 tumor (TART) was documented in 28% of men. While 11KT (3.5x) and 11OHA4 (5.7x) among other
68 adrenal steroids were significantly elevated in men with hypogonadism, in stepwise logistic regression,
69 the only significant independent predictor for hypogonadism were elevated 17-OHP levels (B = 0.006;
70 p = 0.039). Although 11KT (5.2x) and 11OHA4 (3.7x) levels were also significantly higher in women
71 with amenorrhea in comparison to those with a regular cycle, the only significant predictor for
72 amenorrhea were elevated total testosterone levels (B = 1.806; p = 0.040). 11-oxygenated androgens
73 were not different in those with TART and those without. Of note, there were no significant differences
74 in 11OHA4 or 11KT between those with a regular cycle and those currently on hormonal
75 contraceptives.

76 **Conclusions**

77 11-oxygenated androgens do not seem to add additional information for explaining menstrual
78 disturbances and hypogonadism in patients with CAH in comparison to established marker of disease
79 control.

80

81 **Keywords**

82 Congenital adrenal hyperplasia, hypogonadism, menstrual cycle, 11-ketotestosterone, 11-oxygenated
83 androgens

85 **Abbreviations**

86	11KT	11-ketotestosterone
87	11OHA4	11 β -hydroxyandrostenedione
88	17-OHP	17 α -hydroxyprogesterone
89	ACTH	Adrenocorticotrophic hormone
90	AR	Androgen receptor
91	CAH	Congenital adrenal hyperplasia
92	CPA	Cyproterone acetate
93	DHEAS	Dehydroepiandrosterone sulfate
94	ER	Estrogen receptor
95	FC	Fludrocortisone
96	FSH	Follicle-stimulating hormone
97	GC	Glucocorticoid(s)
98	GnRH	Gonadotropin releasing hormone
99	HC	Hydrocortisone
100	HPG	Hypothalamus-pituitary-gonadal
101	LH	Luteinizing hormone
102	PR	Progesterone receptor
103	SERM	Selective estrogen receptor modulator
104	SHBG	Sex hormone binding globulin
105	SV	Simply virilizing
106	SW	Salt-wasting
107	TART	Testicular adrenal rest tumor

108

Acknowledgments

We thank all participants for taking part in this study

Funding

This work was supported by the IFCAH grant 2013 to NR and by the Deutsche Forschungsgemeinschaft (Heisenberg Professorship 325768017 to NR and Projektnummer: 314061271-TRR205 to NR). The authors declare no competing interests.

1. Introduction

Congenital adrenal hyperplasia (CAH) encompasses a group of hereditary autosomal recessive disorders that are characterized by mutations in key enzymes of cortisol synthesis. Among these, patients affected by mutations in the 21-alpha hydroxylase gene are the largest entity (1). Depending on the severity of the underlying mutation, patients are either suffering from isolated glucocorticoid- (simply virilizing form= SV) or additional mineralocorticoid-deficiency, when less than 1-2% of enzymatic activity is retained (salt-wasting = SW). Glucocorticoid deficiency in turn results in ACTH overstimulation due to the loss of hypothalamo-pituitary negative feedback which subsequently drives excessive adrenal androgen production (2).

Hypothalamus-pituitary-gonadal (HPG)-axis disturbances are a common phenomenon in CAH patients of both sexes. In particular in women in the fertile age, menstrual disturbances occur in up to 30% (3-5). The most obvious mechanism for this finding is the inherent extra-gonadal androgen and progesterone production in CAH. Correspondingly, menstrual cycle disturbances in female patients with CAH have been associated with poor treatment control as indicated by increased 17-OHP, testosterone, progesterone and androstenedione levels (6). In line, a recent study from the DSD-life cohort demonstrated that an androstenedione/testosterone ratio ≥ 1 , indicating excessive adrenal testosterone production, is a strong predictor of sub-normal testosterone levels in men with CAH (7). Most of these patients correspondingly present with low or inadequately low gonadotropin levels indicating hypogonadotropic hypogonadism, while some patients also show signs of primary testicular damage mainly due to testicular adrenal rest tumor (TART) formation (7-9)

However, HPG-axis disturbances can also be found in patients who are regarded well controlled based on the aforementioned treatment markers (4,10). The exact culprit for HPG disturbances is therefore not always clear, as all major steroids, namely testosterone, estradiol and progesterone are important parts of the HPG feedback loop (11).

In recent years, a further class of adrenal-derived androgens has come into focus in the context of CAH. These are 11-oxygenated 19-carbon androgens, in particular 11-ketotestosterone (11KT) and 11 β -hydroxyandrostenedione (11OHA4). Androstenedione can be converted to 11OHA4 by 11 β -hydroxylase, then to 11-ketoandrostenedione through the action of 11 β -hydroxysteroid dehydrogenase type 2 and finally to 11KT (12,13). It has been demonstrated that 11KT and its

derivate 11KT-dihydrotestosterone act at the androgen receptor with equal potency to the classic testosterone and dihydrotestosterone (DHT) (14). Correspondingly, it has been shown that these steroids are significantly elevated in patients with classic CAH (15). While it has been suggested that elevated 11KT levels might contribute to HPG-suppression at the hypothalamic and pituitary level, their clinical relevance has still to be determined (16). Although testosterone exerts direct negative effects at the hypothalamic levels via AR binding (17,18), estradiol seems to be the dominant suppressor in this context (19). As 11KT cannot be directly aromatized questions a dominant role in HPG suppression in this context (14).

In the present study, we were therefore interested if 11-oxygenated androgens, in particular 11-KT would add information on HPG-axis disturbances in adult patients with CAH due to 21-hydroxylase deficiency in addition to established markers of disease control.

In detail, we hypothesized that 11KT would be higher in men with hypogonadotropic hypogonadism than in those with eugonadism, that 11OHA4 would be higher in males with TART than in those without and that 11KT and 11OHA4 would be higher in women with menstrual irregularities in contrast to those with eumenorrhoea. In an exploratory analysis we were further interested if 11KT and 11OHA4 would differ between women with a regular cycle and those on oral contraceptive therapy to estimate if these potential covariates should be accounted for in the clinical context if our main hypotheses would hold true.

2. Material and Methods

Subjects

We included 89 patients (N=42 men, N=55 women) of whom 58 were suffering from SW and 31 of the SV form of CAH. All patients were seen at the outpatient clinic of the Medizinische Klinik IV, Klinikum der Universität München, LMU Munich. All patients were directly approached during a regular visit in the outpatient clinic. The recruitment period was from January 2012 to January 2014. The local ethics committee of the Ludwig-Maximilians-Universität München approved the study protocol. All participants provided their written informed consent.

Testicular ultrasound

Testicular ultrasound was performed in the Department of Endocrinology in the University Hospital Munich by a trained sonographer (Siemens Acuson S2000). Testicular ultrasound was performed documenting testicular masses. Greyscale and color Doppler ultrasonography were obtained in the longitudinal and transverse planes using a 15MHz transducer. Data on TART was missing in seven men.

Hormone assays and hormonal control

Blood was drawn in fasting patients in the morning between 8 and 10 a.m., roughly 2 hours after the intake of the morning medication of participants. Concentrations of adrenocorticotrophic hormone (ACTH), sex hormone binding globulin (SHBG) and DHEAS were determined using the Liaison chemiluminescence immunoassays (DiaSorin, Sallugia, Italy).

Total testosterone, 17-OHP, androstenedione, 11-KT and 11OHA4 were quantified by LC-MS/MS. Steroid extraction and quantitation was carried out as previously described (20).

Daily doses of glucocorticoids and mineralocorticoids were evaluated. Equal hydrocortisone doses were calculated according to their suggested androgen-suppressive capacity (hydrocortisone=1, prednisolone=4, dexamethasone=70) and adjusted to the patients' body surface area (2). In men, hypogonadism was defined as having a low testosterone level <12nmol/l (21)(39). Hypogonadotropic hypogonadism was defined as having low testosterone levels with inappropriately normal or low LH/FSH. Secondary amenorrhea was defined as not having had a spontaneous menstrual bleeding during the last six months prior to study inclusion, while irregular cycles were defined as having as cycle length that was less than 21 or more than 35 days (22).

Statistical analysis

Statistical analysis was performed using PASW Statistics (formerly SPSS) Version 22.0 for Windows. Sample characteristics were compared using χ^2 tests for categorical variables and the Mann-Whitney U test for continuous variables.

Spearman correlation was performed for univariate correlations. Partial regression analyses with LH and FSH as a dependent variable and potential influential factors as independent variables were performed adjusted for age and BMI. Separate multivariate regression analyses were used to identify independent contributors for hypogonadism in men and secondary amenorrhea in women. Due to the strong correlation among most steroid measures, variables were mean centered before addition to the

model. A two-block linear regression analysis was carried out to assess the contribution of different variables. Block 1 included age and BMI using a forced entry method. In Block 2, we added CAH-specific covariates using forward stepwise regression analysis. A two-sided P value of <0.05 was considered statistically significant.

3. Results

General characteristics

The median age of the cohort was 28 years (range 18-61). The median GC equivalence dosage was 16.0 mg/m²/d for men and 14.6 mg/m²/d for women. According to the expected (residual) enzymatic activity, thirteen (21.0% of whom data was available) patients were assigned to genotype group 0, 21 (33.9%) to genotype group A, 24 (38.7%) to genotype group B and four (6.5%) patients to genotype group C (23).

Of those investigated, TART was present in eleven patients (28.2%). 23% presented with hypogonadotropic hypogonadism. There were no men with primary hypogonadism.

Thirty seven percent of women were currently receiving hormonal contraceptive therapy. From those without oral contraception and in premenopausal age, 38.7% had a regular cycle while 25.8% had irregular menses and 35.5% were amenorrhoeic. Three women were postmenopausal (6%). At study inclusion, of those with a regular cycle, 75% were in the follicular and 25% in the luteal phase of the cycle (Table 1).

Table 1 General characteristics

		Men		Women			
		N (39)	%	N (50)	%		p
Mutation							
Mutation group	0	8	21	5	10		0.293
	A	12	31	9	18		
	B	8	21	16	32		
	C	2	5	2	4		
	Unknown	9	23	18	36		
Simply virilizing		12	31	19	38		
Salt wasting		27	69	32	64		0.477

TART	Yes	11	28.2	NA	NA		
	unilateral	3		NA	NA		
	bilateral	7		NA	NA		
	No	21	53.8	NA	NA		
	Missing	7	17.9	NA	NA		
Hypogonadism			0				NA
	Eugonadism	30	77	NA	NA		
	Sec. hypogonadismus	9	23	NA	NA		
	Primary hypogonadism	0	0	NA	NA		
Cycle	Oral contraception	NA	NA	16	32		NA
	Regular cycle	NA	NA	12	24	38.7*	
	Follicular	NA	NA	9	12	75%**	
	Luteal	NA	NA	3	8	25%**	
	Irregular menses	NA	NA	8	16	25.8*	
	Secondary amenorrhea	NA	NA	11	22	35.5*	
	Postmenopausal	NA	NA	3	6		
			0		0		
GC	None	0	0	2	4		0.359
	HC	18	46	19	38		
	Predniso-ne/-lone	16	41	24	48		
	Dexa	4	10	3	6		
	HC + Dexa	0	0	3	6		
	Predniso-ne/-lone +Dexa	1	3	0	0		
		Median		Median			
HC Equivalence-dosage (mg/m ²)		14.6		16.0			0.143

243 *Man-Whitney U, X2 test*

244 **Of those not on contraception*

245 ***of those with regular cycle*

246 *NA not applicable*

247 *TART: testicular adrenal rest tumor*

248 *HC: hydrocortisone*

249 *GC: glucocorticoid*

250 *Dexa: Dexamethasone*

251 *TART: Testicular adrenal rest tumor*

252

253 There were no significant differences in androstenedione,17-OHP,11KT and 11OHA4 levels between

254 men and women. (Table 2).

255

256

257 **Table 2 Anthropometric measures and hormone values**

	Men			Women			
	Median	Percentiles		Median	Percentiles		p
		25	75		25	75	
Age	28.0	24.0	40.0	29.0	24.0	38.0	0.990
BMI (kg/m ²)	26.0	22.7	29.9	26.8	22.3	30.8	ND
Waist (cm)	95.0	81.3	100.8	78.0	70.0	92.0	ND
Body fat (%)	25.6	13.1	25.7	34.3	18.5	33.2	ND
Lean mass (%)	57.1	52.5	63.1	44.4	40.1	48.8	ND
LH (U/l)	3.0	1.8	4.7	3.4	0.9	5.7	ND
FSH (U/l)	5.0	2.8	7.2	4.6	2.8	6.9	ND
ACTH (pg/ml)	11.0	6.0	55.0	10.0	4.0	29.0	0.219
Testosterone (nmol/l)	13.0	10.9	16.7	0.5	0.2	1.5	ND
Androstenedione (nmol/l)	3.6	1.1	8.2	2.0	0.9	6.0	0.155
17-OHP (nmol/l)	23.3	5.2	153.6	14.0	2.8	64.5	0.125
11KT (nmol/l)	1.2	0.3	2.4	0.6	0.2	2.4	0.335
11OHA4 (nmol/l)	2.0	0.3	8.0	1.3	0.3	5.5	0.550
DHEAS (µg/ml)	0.3	0.2	0.5	0.0	0.0	0.2	ND
SHBG (nmol/l)	33.5	24.1	39.1	57.8	39.2	145.1	ND
A/T-ratio	0.30	0.1	0.7	3.7	3.5	4.8	ND
11KT/T-ratio	0.1	0.02	0.24	1.2	1.0	1.7	ND
FAI (%)	12.4	9.0	17.2	0.2	0.1	0.8	ND
HOMA-IR	1.6	1.1	2.0	2.2	1.0	3.4	0.190

258 *Mann-Whitney U*
259 *ND not determined*
260 *FAI: free androgen index*
261 *11OHA4: 11-β hydroxyandrostenedione*
262 *11KT: 11-ketotestosterone*
263 *T: Testosterone*
264
265

266 **Correlations between steroid measures**

267 In men, there was a strong positive correlation between 11KT with ACTH (0.845; $p < 0.001$),
268 androstenedione ($R = 0.933$; $p < 0.001$), 17-OHP ($R = 0.942$; $p < 0.001$) and the
269 androstenedione/testosterone (A/T)-ratio ($R = 0.837$; $p < 0.001$). A negative correlation of 11KT with
270 testosterone was only seen on a trend level ($R = -0.278$; $p = 0.087$) and there was no significant

correlation with the free androgen index (FAI). 11OHA4 correlated positively with ACTH ($R = 0.868$; $p < 0.001$), androstenedione (0.944 ; $p < 0.001$), 17-OHP ($R = 0.947$; $p < 0.001$) and the A/T-ratio ($R = 0.857$; $p < 0.001$). 11KT and 11OHA4 also were strongly correlated ($R = 0.976$; $p < 0.001$).

In women, there was a positive correlation of 11KT with ACTH ($R = 0.552$; $p < 0.001$), total testosterone ($R = 0.899$; $p < 0.001$), androstenedione ($R = 0.889$; $p < 0.001$), 17-OHP ($R = 0.915$; $p < 0.001$), DHEAS ($R = 0.618$; $p < 0.001$) and the FAI ($R = 0.780$; $p < 0.001$). 11OHA4 correlated positively with ACTH ($R = 0.604$; $p < 0.001$), total testosterone ($R = 0.875$; $p < 0.001$), androstenedione ($R = 0.886$; $p < 0.001$), 17-OHP ($R = 0.915$; $p < 0.001$), DHEAS ($R = 0.637$; $p < 0.001$) and the FAI ($R = 0.781$; $p < 0.001$). The correlation between 11KT and 11OHA4 was weaker than in men ($R = 0.477$; $p < 0.001$).

Presence of TART

There were no significant differences in steroid measures between those with and without TART. There was also no difference in ACTH or gonadotropin levels, HC equivalence dosage or SV vs. SW (data not shown).

Hypogonadism in men

Androstenedione levels were significantly higher in men with secondary hypogonadism than in those with eugonadism ($4.5x$; $p = 0.023$). A similar pattern could be observed with 17-OHP ($14.4x$; $p = 0.007$), 11KT ($3.5x$; $p = 0.020$), 11OHA4 ($5.7x$, $p = 0.009$) and ACTH ($9.3x$; $p = 0.004$) (Figure 1).

Figure 1 Differences between men with hypogonadism and eugonadism

Fig 1 Androstenedione levels were significantly higher in men with secondary hypogonadism than in those with eugonadism (4.5x; $p = 0.023$). Same was true for 17-OHP (14.4x; $p = 0.007$), 11KT (3.5x; $p = 0.020$), 11OHA4 (5.7x, $p = 0.009$) and ACTH (9.3x; $p = 0.004$). (Boxes represent the first to the third quartile, vertical line indicates medians, crosses indicate outliers).

LH/FSH in men

In men, according to partial correlation analysis, adjusted for BMI and age, there was no significant correlation of LH with any steroid measure. There was also no correlation with HC equivalence dosage, type of GC (HC = 0 vs. synthetic GC = 1) or with regard to SV vs. SW.

In contrast, there were comparably strong negative correlations of androstenedione ($R = -0.330$; $p = 0.048$), 17-OHP ($R = -0.329$; $p = 0.047$), 11KT ($R = -0.368$; $p = 0.025$), 11OHA4 ($R = -0.361$; $p = 0.028$), the A/T-ratio ($R = -0.387$; $p = 0.018$) as well as the KT/T-ratio ($R = -0.383$; $p = 0.019$) with FSH.

There was no significant correlation with LH or FSH when adding KT+T as a new variable, given then idea that both androgens should have equimolar androgenic potency according to the literature.

Predictors of hypogonadism in men

The only significant predictor for hypogonadism in men were elevated 17-OHP levels ($B = 0.006$; $p = 0.039$) in a stepwise logistic regression (0 = Eugonadism, 1= hypogonadism), including age, BMI, ACTH, androstenedione, 17-OHP, DHEAS, 11KT and 11OHA4. As expected, finding also remained significant when adding HC-equivalence dosage as well as HC (0) vs GC (1) to the model (Table 3).

Table 3 Stepwise regression of potential predictors of hypogonadism in men

Variable	B	S.E.	p	Exp(B)	95% C.I.	95% C.I.
					Lower	Upper
Age*	-.037	.048	.435	.963	0.877	1.058
BMI*	-.004	.105	.966	.996	0.811	1.222
17-OHP	.006	.003	.039	1.006	1.000	1.011

*Forced entry including ACTH, androstenedione, 17-OHP, DHEAS, 11KT and 11OHA4 as independent variables.

All variables were mean-centered. C.I. confidence interval

Amenorrhea in women

ACTH (4.3x; $p = 0.003$), androstenedione (2.5x; $p = 0.019$), 17-OHP (8.1x; $p = 0.002$), 11KT (5.2x; $p = 0.002$), 11OHA4 (3.7x; $p = 0.023$) and testosterone (3.1x; $p = 0.007$) were significantly higher in women with amenorrhea versus regular cycling women (Figure 2).

Figure 2 Differences between regular cycling and amenorrhoeic women

Fig 2 ACTH (4.3x; $p = 0.003$), androstenedione (2.5x; $p = 0.019$), 17-OHP (8.1x; $p = 0.002$), 11KT (5.2x; $p = 0.002$), 11OHA4 (3.7x; $p = 0.023$) and testosterone (3.1x; $p = 0.007$) were significantly higher in women with amenorrhea in comparison to those with a regular cycle. (Boxes represent the first to the third quartile, vertical line indicates medians, crosses indicate outliers).

Equivalence dosage of HC was lower (12.7mg/m² vs 16.4mg/m²; $p = 0.019$). There was no difference in terms of GC vs HC use or HOMA-IR. There was also no difference in DHEAS levels and the A/T-ratio. There was no significant difference in these parameters between those with irregular and those with a regular cycle (data not shown).

Oral contraceptive use

Androstenedione ($p = 0.011$), the FAI ($p = 0.001$) and DHEAS ($p = 0.049$) were significantly lower in women with a regular menstrual cycle in comparison to women currently taking an oral contraceptive pill, while there was no difference in total testosterone, 17-OHP, 11KT or 11OHA4 (Figure 3).

Figure 3 Oral contraception vs regular cycle

Fig 3 When comparing those with a regular menstrual cycle with those currently taking an oral contraceptive pill, androstenedione ($p = 0.011$), the FAI ($p = 0.001$) and DHEAS ($p = 0.049$) were significantly lower, while there was no difference in total testosterone, 17-OHP, 11KT or 11OHA4.). (Boxes represent the first to the third quartile, vertical line indicates medians, crosses indicate outliers).

Predictors of amenorrhea

Only higher testosterone levels were significantly associated with amenorrhea ($B = 1.806$; $p = 0.040$) in a logistic regression analysis including age, BMI (Enter) (0 = amenorrhea, 1= regular cycle), ACTH, androstenedione, 17-OHP, DHEAS, total testosterone, free testosterone, the A/T-ratio, 11KT, 11OHA4, and the T/KT-ratio (stepwise) (Table 4).

376

377

378 **Table 4 Stepwise regression of potential predictors of amenorrhea**

Variable	B	S.E.	p	Exp(B)	95% C.I.	95% C.I.
					Lower	Upper
Age*	-0.097	0.111	0.381	.908	0.731	1.127
BMI*	-0.024	0.095	0.804	.977	0.812	1.176
Testosterone	1.806	0.877	0.040	6.085	1.091	33.955
Constant	0.796	0.803	0.321	2.216		

379 **Forced entry; Stepwise including ACTH, androstenedione, 17-OHP, DHEAS, total testosterone, free*
380 *testosterone, the A/T-ratio, 11KT, 11OHA4, and the T/KT-ratio as independent variables. All variables*
381 *were mean-centered. C.I. confidence interval.*

382

383 4. Discussion

384 We could demonstrate in this relatively large cohort that 11-oxygenated androgens are significantly
385 elevated in patients of both sexes with HPG-axis disturbances. They however do not seem to be the
386 most relevant androgens in this context.

387 The prevalence of hypogonadism in men and menstrual irregularities in women in our cohort was
388 comparable to that reported in the literature (7,24) and hence emphasizes that HPG-axis disturbances
389 are still a fairly common issue in this patient population. Despite a significant elevation of 11KT and
390 11OHA4, being in accordance with earlier studies (16), 17-OHP was a better predictor of
391 hypogonadism in male patients. Our data therefore do not indicate a leading role of 11KT in HPG-axis
392 suppression. This may be due to the fact that 11KT cannot be converted into estrogenic steroids and
393 many effects that had originally been attributed to testosterone in men are actually mediated via
394 aromatization to estradiol (25). This also includes sex steroid regulation at the hypothalamus/pituitary
395 level (19).

396 The significant role of 17OHP may be explained by the fact that progesterone is also a very potent
397 suppressor of the HPG-axis in men (26,27). As 17-OHP is a direct metabolite of progesterone, it is a

potent agonist of the PR (28) as also indicated by a strong positive correlation between both steroids in patients with CAH (29).

In contrast to previous work (16) and our initial hypothesis, neither 11KT nor 11OHA4 were elevated in men with TART and most steroid measures, including 11KT and 11OHA4 showed a negative instead of a positive correlation with FSH as a potential marker of gonadal damage. Although our cohort was age-wise comparable to those adult patients reported by Turcu et al., a considerable proportion of their patients with TART were children. While TARTs in younger patients might still respond to HPA-axis suppression, they seem to become less modifiable in the long-term due to fibrotic modifications (30). In line, presence of TART has been associated with poor treatment quality in some (8) but not all studies (9,31). Despite the factor of age, we cannot exclude that there were further differences in non-recorded potential confounders such as long-term disease control distinguishing our patient groups.

11KT and 11OHA4 levels were also higher in women with secondary amenorrhea than in those with a regular cycle, as having been reported before (16). But again, when adding other markers of disease control to our model, testosterone was superior in explaining amenorrhea. Correspondingly, menstrual cycle disturbances in female patients with CAH have been associated with poor androgen control (6). Testosterone modulates GnRH-pulse frequency and therefore interferes with the complex hormonal interplay during the menstrual cycle (32). In addition, it also has direct effects on the endometrium (33).

Of note, there were no significant differences in 11KT or 11OHA4 between those with a regular cycle and those currently taking hormonal contraceptives. This may be due to a lower binding affinity for SHBG that has been suggested but not yet demonstrated for these steroids. This could be of clinical relevance, as this might explain why some patients benefit less from oral contraceptive treatment with regard to hyperandrogenic symptoms such as hirsutism and acne (34). However, prospective studies are needed to substantiate this finding.

There are several limitations of our study. Firstly, due to the cross-sectional design we can only show associations and no causality between dependent and independent variables. Prospective studies with modifying interventions are therefore needed. A further limitation in this context is that, in contrast to the general recommendation, the definition on hypogonadism in our study was based on a single, instead of two testosterone measures in the morning (21). However, diurnal variance of testosterone

and LH in CAH do generally differ from the general male population due to the extra-gonadal androgen production and also depend on GC pharmacokinetics (1). A further limitation of our study is that we only used a single steroid measurement in the morning for our analyses. Steroid measurements from blood drawn before the intake of the morning GC dosage might therefore yield other results. However, all patients included were either receiving a morning dosage of HC or prednisolone or an evening dosage of dexamethasone which show, given the wide inter-individual variability, a comparable suppression profile for the chosen time window (35,36).

Lastly, although we investigated a large group of adult patients with classic CAH, given the rarity of the disease, subgroups were rather small, stepwise regression had to be used for our final models. Nonetheless, given the strong differences in steroid markers between groups we consider our results to be valid.

5. Conclusion

In the present study, 11KT and 11OHA4 did not seem to add additional information to the understanding of HPG-axis disturbances in CAH. Further studies have to show if 11oxC19 steroids are of relevance for explaining for other health issues in CAH. It might be of particular interest, if they could be a superior biomarker of disease control. To our knowledge it has not yet been shown to what extent 11-oxygenated androgens show a diurnal variation, potentially addressing the still problematic issue of timing of blood sampling with regard to different GC treatment regimens. Former approaches to overcome these restrictions like serial salivary (36) or blood sampling (37), or hair steroid measures (52) are on the one hand very time consuming and on the other hand have so far not yet been proven to be superior in terms of predicting clinically relevant long-term outcomes. Lastly, it would have to be demonstrated that 11KT can be independently targeted by treatment-modification, independent of other adrenal androgens.

454

455

456

457

458 6. References

459

- 460 1. Speiser PW, Arlt W, Auchus RJ, Baskin LS, Conway GS, Merke DP, Meyer-Bahlburg HFL,
461 Miller WL, Murad MH, Oberfield SE, White PC. Congenital Adrenal Hyperplasia Due to Steroid
462 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline. *J Clin*
463 *Endocrinol Metab.* 2018;103(11):4043-4088.
- 464 2. White PC, Speiser PW. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
465 *Endocrine reviews.* 2000;21(3):245-291.
- 466 3. Turcu AF, Mallappa A, Elman MS, Avila NA, Marko J, Rao H, Tsodikov A, Auchus RJ, Merke
467 DP. 11-Oxygenated Androgens Are Biomarkers of Adrenal Volume and Testicular Adrenal
468 Rest Tumors in 21-Hydroxylase Deficiency. *The Journal of clinical endocrinology and*
469 *metabolism.* 2017;102(8):2701-2710.
- 470 4. Stikkelbroeck NM, Sweep CF, Braat DD, Hermus AR, Otten BJ. Monitoring of menstrual
471 cycles, ovulation, and adrenal suppression by saliva sampling in female patients with 21-
472 hydroxylase deficiency. *Fertility and sterility.* 2003;80(4):1030-1036.
- 473 5. RICHARDS GE, GRUMBACH MM, KAPLAN SL, CONTE FA. The Effect of Long Acting
474 Glucocorticoids on Menstrual Abnormalities in Patients with Virilizing Congenital Adrenal
475 Hyperplasia*. *The Journal of Clinical Endocrinology & Metabolism.* 1978;47(6):1208-1215.
- 476 6. Bachelot A, Chakhtoura Z, Plu-Bureau G, Coudert M, Coussieu C, Badachi Y, Dulon J,
477 Charbit B, Touraine P, Group CS. Influence of hormonal control on LH pulsatility and secretion
478 in women with classical congenital adrenal hyperplasia. *European journal of endocrinology.*
479 *2012;167(4):499.*
- 480 7. Engels M, Gehrman K, Falhammar H, Webb EA, Nordenstrom A, Sweep F, Span PN, van
481 Herwaarden AE, Rohayem J, Richter-Unruh A. Gonadal function in adult male patients with
482 congenital adrenal hyperplasia. *European journal of endocrinology.* 2018;EJE-17-0862.
- 483 8. King TF, Lee MC, Williamson EE, Conway GS. Experience in optimizing fertility outcomes in
484 men with congenital adrenal hyperplasia due to 21 hydroxylase deficiency. *Clinical*
485 *endocrinology.* 2016;84(6):830-836.
- 486 9. Reisch N, Flade L, Scherr M, Rottenkolber M, Pedrosa Gil F, Bidlingmaier M, Wolff H,
487 Schwarz H-P, Quinkler M, Beuschlein F. High prevalence of reduced fecundity in men with
488 congenital adrenal hyperplasia. *The Journal of Clinical Endocrinology & Metabolism.*
489 *2009;94(5):1665-1670.*
- 490 10. Richards G, Grumbach M, Kaplan S, Conte F. The effect of long acting glucocorticoids on
491 menstrual abnormalities in patients with virilizing congenital adrenal hyperplasia. *The Journal*
492 *of Clinical Endocrinology & Metabolism.* 1978;47(6):1208-1215.
- 493 11. Kaprara A, Huhtaniemi IT. The hypothalamus-pituitary-gonad axis: tales of mice and men.
494 *Metabolism.* 2018;86(3-17).
- 495 12. Turcu AF, Rege J, Auchus RJ, Rainey WE. 11-Oxygenated androgens in health and disease.
496 *Nature Reviews Endocrinology.* 2020;1-13.
- 497 13. Turcu AF, Auchus RJ. Clinical significance of 11-oxygenated androgens. *Current opinion in*
498 *endocrinology, diabetes, and obesity.* 2017;24(3):252.
- 499 14. Imamichi Y, Yuhki K-i, Orisaka M, Kitano T, Mukai K, Ushikubi F, Taniguchi T, Umezawa A,
500 Miyamoto K, Yazawa T. 11-ketotestosterone is a major androgen produced in human gonads.
501 *The Journal of Clinical Endocrinology & Metabolism.* 2016;101(10):3582-3591.
- 502 15. Turcu AF, Nanba AT, Chomic R, Upadhyay SK, Giordano TJ, Shields JJ, Merke DP, Rainey
503 WE, Auchus RJ. Adrenal-derived 11-oxygenated 19-carbon steroids are the dominant

- androgens in classic 21-hydroxylase deficiency. *European journal of endocrinology*. 2016;174(5):601-609.
16. Turcu AF, Mallappa A, Elman MS, Avila NA, Marko J, Rao H, Tsodikov A, Auchus RJ, Merke DP. 11-Oxygenated androgens are biomarkers of adrenal volume and testicular adrenal rest tumors in 21-hydroxylase deficiency. *The Journal of Clinical Endocrinology & Metabolism*. 2017;102(8):2701-2710.
17. Resko JA, Ellinwood WE. Negative feedback regulation of gonadotropin secretion by androgens in fetal rhesus macaques. *Biology of reproduction*. 1985;33(2):346-352.
18. KEENAN BS, EBERLE AJ, SPARROW JT, GREGER NG, PANKO WB. Dihydrotestosterone heptanoate: synthesis, pharmacokinetics, and effects on hypothalamic-pituitary-testicular function. *The Journal of Clinical Endocrinology & Metabolism*. 1987;64(3):557-562.
19. Raven G, de Jong FH, Kaufman J-M, de Ronde W. In men, peripheral estradiol levels directly reflect the action of estrogens at the hypothalamo-pituitary level to inhibit gonadotropin secretion. *The Journal of Clinical Endocrinology & Metabolism*. 2006;91(9):3324-3328.
20. Hawley JM, Adaway JE, Owen LJ, Keevil BG. Development of a total serum testosterone, androstenedione, 17-hydroxyprogesterone, 11 β -hydroxyandrostenedione and 11-ketotestosterone LC-MS/MS assay and its application to evaluate pre-analytical sample stability. *Clinical Chemistry and Laboratory Medicine (CCLM)*. 2020;58(5):741-752.
21. Arver S, Lehtihet M. Current guidelines for the diagnosis of testosterone deficiency. *Advances in the management of testosterone deficiency*. Vol 37: Karger Publishers; 2009:5-20.
22. Master-Hunter T, Heiman DL. Amenorrhea: evaluation and treatment. *American family physician*. 2006;73(8):1374-1382.
23. Krone N, Braun A, Roscher AA, Knorr D, Schwarz HP. Predicting phenotype in steroid 21-hydroxylase deficiency? Comprehensive genotyping in 155 unrelated, well defined patients from southern Germany. *The Journal of Clinical Endocrinology & Metabolism*. 2000;85(3):1059-1065.
24. Reichman DE, White PC, New MI, Rosenwaks Z. Fertility in patients with congenital adrenal hyperplasia. *Fertility and sterility*. 2014;101(2):301-309.
25. Finkelstein JS, Lee H, Burnett-Bowie S-AM, Pallais JC, Yu EW, Borges LF, Jones BF, Barry CV, Wulczyn KE, Thomas BJ. Gonadal steroids and body composition, strength, and sexual function in men. *New England Journal of Medicine*. 2013;369(11):1011-1022.
26. Auer MK, Fuss J, Stalla GK, Athanasoulia AP. Twenty years of endocrinologic treatment in transsexualism: analyzing the role of chromosomal analysis and hormonal profiling in the diagnostic work-up. *Fertility and sterility*. 2013;100(4):1103-1110.
27. Fuss J, Claro L, Ising M, Biedermann SV, Wiedemann K, Stalla GK, Briken P, Auer MK. Does sex hormone treatment reverse the sex-dependent stress regulation? A longitudinal study on hypothalamus-pituitary-adrenal (HPA) axis activity in transgender individuals. *Psychoneuroendocrinology*. 2019;104(228-237).
28. Attardi BJ, Zeleznik A, Simhan H, Chiao JP, Mattison DR, Caritis SN, Network OFPRU. Comparison of progesterone and glucocorticoid receptor binding and stimulation of gene expression by progesterone, 17-alpha hydroxyprogesterone caproate, and related progestins. *American journal of obstetrics and gynecology*. 2007;197(6):599. e591-599. e597.
29. HUGHES IA, WINTER JS. The relationships between serum concentrations of 17OH-progesterone and other serum and urinary steroids in patients with congenital adrenal hyperplasia. *The Journal of Clinical Endocrinology & Metabolism*. 1978;46(1):98-104.
30. Claahsen-Van der Grinten H, Otten B, Stikkelbroeck M, Sweep F, Hermus A. Testicular adrenal rest tumours in congenital adrenal hyperplasia. *Best practice & research Clinical endocrinology & metabolism*. 2009;23(2):209-220.
31. Reisch N, Scherr M, Flade L, Bidlingmaier M, Schwarz H-P, Muller-Lisse U, Reincke M, Quinkler M, Beuschlein F. Total adrenal volume but not testicular adrenal rest tumor volume is associated with hormonal control in patients with 21-hydroxylase deficiency. *The Journal of Clinical Endocrinology & Metabolism*. 2010;95(5):2065-2072.
32. Melrose P, Gross L. Steroid effects on the secretory modalities of gonadotropin-releasing hormone release. *Endocrinology*. 1987;121(1):190-199.
33. Rose GL, Dowsett M, Mudge JE, White JO, Jeffcoate SL. The inhibitory effects of danazol, danazol metabolites, gestrinone, and testosterone on the growth of human endometrial cells in vitro. *Fertility and sterility*. 1988;49(2):224-228.
34. Martin KA, Chang RJ, Ehrmann DA, Ibanez L, Lobo RA, Rosenfield RL, Shapiro J, Montori VM, Swiglo BA. Evaluation and treatment of hirsutism in premenopausal women: an endocrine society clinical practice guideline. *The Journal of Clinical Endocrinology & Metabolism*. 2008;93(4):1105-1120.

- 565 **35.** Charmandari E, Matthews DR, Johnston A, Brook CG, Hindmarsh PC. Serum cortisol and 17-
566 hydroxyprogesterone interrelation in classic 21-hydroxylase deficiency: is current replacement
567 therapy satisfactory? The Journal of Clinical Endocrinology & Metabolism. 2001;86(10):4679-
568 4685.
- 569 **36.** Großschl M, Rauh M, Dörr HG. Cortisol and 17-hydroxyprogesterone kinetics in saliva after
570 oral administration of hydrocortisone in children and young adolescents with congenital
571 adrenal hyperplasia due to 21-hydroxylase deficiency. The Journal of Clinical Endocrinology &
572 Metabolism. 2002;87(3):1200-1204.
- 573 **37.** Young M, Walker R, Riad-Fahmy D, Hughes I. Androstenedione rhythms in saliva in
574 congenital adrenal hyperplasia. Archives of disease in childhood. 1988;63(6):624-628.
- 575